WST

West Pharmaceutical Services, Inc. - 2004 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: West Pharmaceutical Services, Inc.
Reporting Period: Fiscal year ended December 31, 2004
Business Overview: The Company is a leading global manufacturer of primary packaging components and systems for injectable drug delivery, including elastomeric stoppers, aluminum seals, and plastic closures. It operates in a single reportable segment (Pharmaceutical Systems) with three operating units: Americas, Europe/Asia, and the Device Group. The Company serves major pharmaceutical, biotechnology, and medical device companies.

Key Financial Metrics (2004)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 12% to $541.6 million, driven by a 14% increase in international sales (partially due to foreign currency translation) and a 10% increase in U.S. sales. Growth was led by specially treated stoppers and increased demand for anti-counterfeiting features.
• Margin Compression: Gross margin declined to 28.8% from 31.7%. This was primarily due to $11.6 million in incremental manufacturing costs related to interim production processes following the 2003 Kinston, NC plant explosion. Unlike 2003, these costs were not offset by insurance reimbursements as the settlement was finalized in the prior year.
• Operating Profit Decline: Operating profit dropped 32% to $48.2 million. This decrease reflects the loss of the $17.3 million insurance settlement gain recorded in 2003, higher SG&A costs (including $5.1 million in stock-based compensation), and the aforementioned manufacturing costs.
• Discontinued Operations: The Company classified its drug delivery business and clinical services unit as discontinued operations. This resulted in a net loss of $14.1 million in 2004, compared to $11.0 million in 2003.

Guidance, Outlook, and Risks

• Divestiture: In December 2004, the Company agreed to sell its drug delivery business to Archimedes Pharma Limited for $7.1 million in cash and debt assumption, plus a 14% ownership interest. The transaction closed in February 2005.
• Outlook: Management expects gross margins to improve to approximately 30% in 2005 as the new Kinston facility reaches full utilization, though this may be offset by higher raw material costs (oil-based resins) and depreciation.
• Capital Allocation: The Board approved a plan to repatriate up to $70 million in foreign earnings to pay down domestic debt, expecting a tax expense of $2 million to $4 million in Q1 2005.
• Key Risks:
  • Supply Chain: Reliance on single-source suppliers for critical raw materials (elastomers, aluminum, plastic) creates supply interruption risks.
  • Regulatory: Extensive FDA regulation impacts manufacturing and testing; non-compliance could halt operations.
  • Legal: Ongoing litigation related to the 2003 Kinston explosion, though the Company believes insurance coverage is sufficient.
  • Currency: Approximately 50% of sales are international, exposing results to foreign exchange fluctuations.

Investor Verification Checklist

• Kinston Recovery: Verify the operational status and capacity utilization of the new Kinston molding facility to confirm margin recovery projections.
• Discontinued Operations: Confirm the final closing details and financial impact of the drug delivery business sale to Archimedes Pharma.
• Tax Repatriation: Monitor Q1 2005 earnings for the specific tax expense associated with the $70 million foreign earnings repatriation plan.
• Raw Material Costs: Track pricing trends for synthetic rubber, aluminum, and plastic resins to assess pressure on gross margins.
• Customer Concentration: Note that Becton Dickinson (BD) accounted for 11% of 2004 sales; monitor the stability of this key relationship.